Researchers from Fudan University (Shanghai, China) and collaborators tested the use of senescent tumor cell (STC)-derived nanovesicles to enable spatiotemporally confined immune responses for selective clearance of radiotherapy-induced STCs.
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy or chemotherapy, where treatment-induced fibrosis is a common complication associated with therapy. Since fibrosis is mostly driven by dysregulation of the Rho-ROCK signaling axis, researchers from Australia have investigated the potential of modulating ROCK2 with the small-molecule inhibitor RX-10616 for its potential antifibrotic effect combined with radiotherapy in patient-derived murine models of HNSCC.
Mabwell (Shanghai) Bioscience Co. Ltd. on May 30 gained Chinese approval of Mailisheng (albipagrastim alfa; 8MW-0511) as a subcutaneous injection to treat febrile neutropenia induced by myelosuppressive anticancer treatment, such as radiotherapy and chemotherapy.
Mabwell (Shanghai) Bioscience Co. Ltd. on May 30 gained Chinese approval of Mailisheng (albipagrastim alfa; 8MW-0511) as a subcutaneous injection to treat febrile neutropenia induced by myelosuppressive anticancer treatment, such as radiotherapy and chemotherapy.
Researchers at the University of Chicago have shed light on the role of tumor-promoting factors induced by radiotherapy and their potential impact on future therapeutic strategies. The article, published in Nature on May 14, 2025, points to radiation-induced amphiregulin as a key driver of tumor metastasis.
Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer, accounting for nearly 50% of thyroid cancer-related deaths. Given its poor prognosis, the identification of new therapeutic strategies is a critical medical need. Molecular radiotherapy is an emerging field in oncology, and CD44v6, a cell surface antigen overexpressed in several cancers, has been proposed as a promising target for ATC treatment.
Although radiotherapy is widely used in cancer treatment, its effects on the tumor microenvironment (TME) can be immunosuppressive as well as immunostimulatory. Fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in several tumors, with higher levels linked to a weakened immune response to immune checkpoint blockade in patients.
Chinese researchers and their collaborators have published data on the bifunctional antibody JS-201, which exerts dual targeting of PD-1 and TGF-β signaling, for the potential treatment of cancer and its protective role against radiation-induced lung injury.
Cellbion Co. Ltd. debuted on the tech-heavy Kosdaq board of the Korea Exchange Oct. 16, with share prices closing upward at ₩20,650 (US$14.94) – outdoing its initial price of ₩15,000 per share for 1.9 million shares.
Cellbion Co. Ltd. debuted on the tech-heavy Kosdaq board of the Korea Exchange Oct. 16, with share prices closing upward at ₩20,650 (US$14.94) – outdoing its initial price of ₩15,000 per share for 1.9 million shares.
